Merit Medical Systems (MMSI) Bank of America SMID Cap Virtual Conference summary
Event summary combining transcript, slides, and related documents.
Bank of America SMID Cap Virtual Conference summary
12 Aug, 2026Conference overview
Event featured a fireside chat with the CFO, focusing on strategic planning and business evolution.
Discussion covered recent leadership transition and the ongoing development of a new long-range plan (LRP).
Emphasis on the company's eight business platforms and a new reporting structure to enhance transparency.
Board changes and new executive leadership are seen as positive for culture and accountability.
The event highlighted the breadth of analyst coverage and engagement opportunities for investors.
Strategic initiatives and business transformation
Foundations for Growth initiative began over five years ago to prepare for leadership succession and process improvements.
New reporting divides business into Foundational and Therapeutic platforms, clarifying growth sources and value drivers.
Accountability is now pushed down to platform leads, aligning internal operations with external communications.
Strategic planning is ongoing, with a new LRP expected to be announced around the fourth quarter.
Focus remains on revenue growth, operating margin expansion, and free cash flow as key performance metrics.
Financial performance and guidance
Operating margin expanded by 850 basis points since December 2019, with a target of 950 basis points by end of 2026.
Q2 organic growth was the strongest in three years, driven by recovery in OEM and successful recall management.
Full-year revenue guidance was raised to approximately 7–7.5% growth at the midpoint.
Seasonal trends are expected, with a typical Q3 slowdown and Q4 rebound.
Gross margin expansion attributed to pricing discipline, product mix, and operational efficiencies.
Latest events from Merit Medical Systems
- On track for strategic targets, expanding through innovation and M&A, with strong execution focus.MMSI
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 delivered double-digit revenue and profit growth, prompting raised full-year guidance.MMSI
Q2 2026 - WRAPSODY FDA approval and robust global growth highlight a strong year and future innovation platform.MMSI
43rd Annual J.P. Morgan Healthcare Conference - Imminent Rhapsody data, strong margins, and strategic growth initiatives drive positive outlook.MMSI
Wells Fargo 2024 Healthcare Conference - Double-digit 2025 growth and strong 2026 outlook, despite tariff and divestiture risks.MMSI
Q4 2025 - Strong 2025 growth, new leadership, and innovation drive global expansion and margin gains.MMSI
44th Annual J.P. Morgan Healthcare Conference - Q2 2025 revenue up 13.2%, strong margins, raised guidance, but risks from tariffs and acquisitions.MMSI
Q2 2025 - Q3 revenue up 7.8% and 2024 guidance raised on strong growth and acquisitions.MMSI
Q3 2024 - FY2024 saw robust growth; FY2025 guidance calls for 8–10% revenue and margin expansion.MMSI
Q4 2024